Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indeglitazar
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Indeglitazar is an orally available small molecule drug that acts as a pan-agonist of peroxisome proliferator-activated receptors (PPARs), targeting all three subtypes—PPAR alpha, delta, and gamma. It is a full agonist of PPAR alpha and a partial agonist of both PPAR gamma and delta. This pharmacological profile was designed to provide metabolic benefits with potentially fewer side effects compared to full activators. Indeglitazar demonstrated significant improvements in glucose, insulin, triglycerides, cholesterol, and free fatty acid levels in preclinical models of diabetes and obesity. Unlike some other PPAR agonists that can cause weight gain, indeglitazar showed weight-neutral or even weight-reducing effects in animal studies. The drug advanced to phase II clinical trials for type 2 diabetes mellitus but development was discontinued due to concerns over the safety profile associated with the class[3][4][5].
- Other names
- indeglitazar [USAN]835619-41-5
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)PPARD (Peroxisome proliferator–activated receptor delta)
Beyond the preview
Go deeper on Indeglitazar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indeglitazar.